Literature DB >> 15314226

Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification.

Loen M Hansford1, Wayne D Thomas, Joanna M Keating, Catherine A Burkhart, Anne E Peaston, Murray D Norris, Michelle Haber, Patricia J Armati, William A Weiss, Glenn M Marshall.   

Abstract

The mechanisms causing persistence of embryonal cells that later give rise to tumors is unknown. One tumorigenic factor in the embryonal childhood tumor neuroblastoma is the MYCN protooncogene. Here we show that normal mice developed neuroblast hyperplasia in paravertebral ganglia at birth that completely regressed by 2 weeks of age. In contrast, ganglia from MYCN transgenic (TH-MYCN) mice demonstrated a marked increase in neuroblast hyperplasia and MycN expression during week 1. Regression of neuroblast hyperplasia was then delayed and incomplete before neuroblastoma tumor formation at 6 and 13 weeks in homo- and hemizygote mice, respectively. Paravertebral neuronal cells cultured from perinatal TH-MYCN mice exhibited 3- to 10-fold resistance to nerve growth factor (NGF) withdrawal, compared with normal mice. Both low- and high-affinity NGF receptors were expressed in perinatal neuroblast hyperplasia but not in neuroblastoma tumor tissue. MYCN transgene amplification was present at low levels in perinatal neuroblast hyperplasia from both homo- and hemizygote TH-MYCN mice. However, only in hemizygous mice did tumor formation correlate with a stepwise increase in the frequency of MYCN amplification. These data suggest that inappropriate perinatal MycN expression in paravertebral ganglia cells from TH-MYCN mice initiated tumorigenesis by altering the physiologic process of neural crest cell deletion. Persisting embryonal neural crest cells underwent further changes, such as MYCN amplification and repression of NGF receptor expression, during tumor progression. Our studies provide a model for studying perinatal factors influencing embryonal tumor initiation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15314226      PMCID: PMC515113          DOI: 10.1073/pnas.0401083101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

Review 1.  N-myc transcription molecule and oncoprotein.

Authors:  Wayne D Thomas; Anna Raif; Loen Hansford; Glenn Marshall
Journal:  Int J Biochem Cell Biol       Date:  2004-05       Impact factor: 5.085

2.  Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line.

Authors:  A Negroni; S Scarpa; A Romeo; S Ferrari; A Modesti; G Raschellà
Journal:  Cell Growth Differ       Date:  1991-10

3.  The biological effects of antisense N-myc expression in human neuroblastoma.

Authors:  M L Schmidt; H R Salwen; C F Manohar; N Ikegaki; S L Cohn
Journal:  Cell Growth Differ       Date:  1994-02

4.  Congenital neuroblastoma, neuroblastoma in situ, and the normal fetal development of the adrenal.

Authors:  Y Ikeda; J Lister; J M Bouton; M Buyukpamukcu
Journal:  J Pediatr Surg       Date:  1981-08       Impact factor: 2.545

5.  Relationship between bcl-2 and myc gene expression in human neuroblastoma.

Authors:  N Ikegaki; M Katsumata; Y Tsujimoto; A Nakagawara; G M Brodeur
Journal:  Cancer Lett       Date:  1995-05-08       Impact factor: 8.679

6.  Inverse relationship between trk expression and N-myc amplification in human neuroblastomas.

Authors:  A Nakagawara; M Arima; C G Azar; N J Scavarda; G M Brodeur
Journal:  Cancer Res       Date:  1992-03-01       Impact factor: 12.701

7.  Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma.

Authors:  A Nakagawara; M Arima-Nakagawara; N J Scavarda; C G Azar; A B Cantor; G M Brodeur
Journal:  N Engl J Med       Date:  1993-03-25       Impact factor: 91.245

8.  Analysis of cell cycle-related gene expression in postmitotic neurons: selective induction of Cyclin D1 during programmed cell death.

Authors:  R S Freeman; S Estus; E M Johnson
Journal:  Neuron       Date:  1994-02       Impact factor: 17.173

9.  Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma.

Authors:  Catherine A Burkhart; Andy J Cheng; Janice Madafiglio; Maria Kavallaris; Mario Mili; Glenn M Marshall; William A Weiss; Levon M Khachigian; Murray D Norris; Michelle Haber
Journal:  J Natl Cancer Inst       Date:  2003-09-17       Impact factor: 13.506

10.  Defects of embryonic organogenesis resulting from targeted disruption of the N-myc gene in the mouse.

Authors:  S Sawai; A Shimono; Y Wakamatsu; C Palmes; K Hanaoka; H Kondoh
Journal:  Development       Date:  1993-04       Impact factor: 6.868

View more
  68 in total

1.  Pediatric oncology: G-CSF counteracts chemotherapy toxicity in neuroblastoma.

Authors:  Heidi Russell; Jason M Shohet
Journal:  Nat Rev Clin Oncol       Date:  2010-11-23       Impact factor: 66.675

Review 2.  Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma.

Authors:  Louis Chesler; William A Weiss
Journal:  Semin Cancer Biol       Date:  2011-09-21       Impact factor: 15.707

3.  Molecular imaging of neuroblastoma progression in TH-MYCN transgenic mice.

Authors:  Carmelo Quarta; Erika Cantelli; Cristina Nanni; Valentina Ambrosini; Daniela D'ambrosio; Korinne Di Leo; Silvia Angelucci; Federico Zagni; Filippo Lodi; Mario Marengo; William A Weiss; Andrea Pession; Roberto Tonelli; Stefano Fanti
Journal:  Mol Imaging Biol       Date:  2013-04       Impact factor: 3.488

4.  Redefining functional MYCN gene signatures in neuroblastoma.

Authors:  Jason Matthew Shohet
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-08       Impact factor: 11.205

Review 5.  Involvement of midkine in neuroblastoma tumourigenesis.

Authors:  S Kishida; K Kadomatsu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

6.  Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.

Authors:  Shizhen Zhu; Jeong-Soo Lee; Feng Guo; Jimann Shin; Antonio R Perez-Atayde; Jeffery L Kutok; Scott J Rodig; Donna S Neuberg; Daniel Helman; Hui Feng; Rodney A Stewart; Wenchao Wang; Rani E George; John P Kanki; A Thomas Look
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

7.  MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development.

Authors:  Goleeta Alam; Hongjuan Cui; Huilin Shi; Liqun Yang; Jane Ding; Ling Mao; William A Maltese; Han-Fei Ding
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

8.  Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis.

Authors:  Tal Teitz; Madoka Inoue; Marcus B Valentine; Kejin Zhu; Jerold E Rehg; Wei Zhao; David Finkelstein; Yong-Dong Wang; Melissa D Johnson; Christopher Calabrese; Marcelo Rubinstein; Razqallah Hakem; William A Weiss; Jill M Lahti
Journal:  Cancer Res       Date:  2013-03-27       Impact factor: 12.701

Review 9.  Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma.

Authors:  Nicholas F Evageliou; Michael D Hogarty
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

10.  ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.

Authors:  Michael D Hogarty; Murray D Norris; Kimberly Davis; Xueyuan Liu; Nicholas F Evageliou; Candace S Hayes; Bruce Pawel; Rong Guo; Huaqing Zhao; Eric Sekyere; Joanna Keating; Wayne Thomas; Ngan Ching Cheng; Jayne Murray; Janice Smith; Rosemary Sutton; Nicola Venn; Wendy B London; Allen Buxton; Susan K Gilmour; Glenn M Marshall; Michelle Haber
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.